Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
131 hedge funds and large institutions have $895M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
70% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 33
10% more funds holding
Funds holding: 119 → 131 (+12)
14% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $3.86M
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
30% less capital invested
Capital invested by funds: $1.28B → $895M (-$390M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$10.6M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.65M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$7.85M |
| 4 |
CI
CPMG Inc
Dallas,
Texas
|
+$6.77M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$21.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.87M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.21M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.74M |
RETA Hedge Fund Activity: Q4 2018 in Review
131 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2018, worth a combined $895M — down 30% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RETA positions and 11 closed out — a net gain of 13 holders — while 56 added to existing stakes and 33 trimmed.
The largest buyer was Prosight Management, adding an estimated $10.6M. The largest seller was Point72 Asset Management, cutting an estimated $27.4M.
- 131 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2018, up from 119 in Q3 2018.
- Funds reported $895M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2018, down 30% quarter-over-quarter.
- 24 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2018 and 11 closed out, a net change of +13 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2018 was Prosight Management, an estimated $10.6M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2018 was Point72 Asset Management, an estimated $27.4M sold.
Based on aggregated 13F filings for Q4 2018.